AstraZeneca and Bristol Myers Squibb merger talks
3 outlets covered the same story. Here's how their headlines landed on the −5 (Far Left) to +5 (Far Right) spectrum — a 0.0-point gap between the most-left and most-right framing.
How the coverage framed it
Coverage of the AstraZeneca and Bristol Myers Squibb merger talks was largely uniform across all three outlets, with a bias spread of just 0.0 points — indicating no meaningful ideological divergence. All three headlines employed plain, wire-service language to convey the same core facts: that talks were underway and that a figure around $400 billion was involved. The Financial Times and NeutralNews both used the neutral verb phrase "holds talks" or "hold talks," while the Wall Street Journal focused instead on immediate market reaction, noting that "AstraZeneca shares drop, Bristol Myers Squibb's climb." This difference is stylistic rather than ideological — the WSJ emphasized investor impact while the other outlets foregrounded the deal's reported scale. None of the headlines introduced evaluative language, political framing, or editorial characterization, reflecting straightforward business reporting consistent with standard financial news conventions.
- +0.0Wall Street Journal · CenterAstraZeneca Shares Drop, Bristol Myers Squibb’s Climb After Merger Talks Reports
- ▸ neutral market framing 'drop/climb' — factual
- ▸ wire-style construction, no ideological signal
- +0.0Financial Times · CenterAstraZeneca holds talks with Bristol Myers Squibb over $400bn tie-up
- ▸ neutral 'holds talks' — plain factual verb
- ▸ wire-style construction
- +0.0Neutral News · CenterAstraZeneca and Bristol Myers Squibb Hold Talks on Reported $400 Billion Merger
- ▸ neutral 'hold talks' — plain wire style
- ▸ factual construction, no ideological signal
Scores are AI estimates of headline language, not factual ratings. Each headline is scored 0 (neutral) outward to Far Left / Far Right by Claude and Grok.